We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SARomics Biostructures Brings in New Strategic Owners
News

SARomics Biostructures Brings in New Strategic Owners

SARomics Biostructures Brings in New Strategic Owners
News

SARomics Biostructures Brings in New Strategic Owners

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SARomics Biostructures Brings in New Strategic Owners"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SARomics Biostructures AB has announced that Innovationsbron AB and Lund University Innovation System AB (LUIS AB) are investing in and becoming new co-owners of the company alongside the founders.

The new investment will allow the company to expand its primary business of generating 3D structural information of proteins and protein-ligand complexes.

SARomics Biostructures is a major user of MAX-lab, the Swedish national synchrotron facility in Lund, and aims to position itself as a leading European structural biology service provider when the new world-class MAX IV synchrotron opens in 2015.

Linus Wiebe, CEO of LUIS said “SARomics Biostructures has shown the commercial potential of MAX-lab and we believe that our strategic investment will leverage the company to take full advantage of MAX IV in the future.”

SARomics Biostructures gene-to-structure platform has successfully been applied to determine structures of many important drug targets, biopharmaceuticals, and industrial enzymes for partners from both the life science industry and academia worldwide.

The company is currently expanding its off-the-shelf portfolio of “ready made” crystal structures of important drug targets and will also engage in internal lead discovery programs.

Advertisement